Spanish Red Biotech Pipeline

MSD

Pembrolizumab/MK-7684

Type: Biodrugs/ Drugs
Therapeutic area: Cancer
Indication: Pembrolizumab in combination with anti-TIGIT or Pembrolizumab in combination with anti-TIGIT plus Docetaxel in metastasic non small lung cancer with progressive disease after treatment with a platinum doublet chemotherapy or immunotheraphy
Phase: 2Phase II in Spain, 1Phase I